Eisai traded at 7,867.00 this Friday February 3rd, decreasing 68.00 or 0.86 percent since the previous trading session. Looking back, over the last four weeks, Eisai lost 3.84 percent. Over the last 12 months, its price rose by 36.65 percent. Looking ahead, we forecast Eisai to be priced at 7,877.64 by the end of this quarter and at 7,116.58 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
M3 Inc 3,720.00 72.00 1.97% -14.36%
Kyowa Hakko Kirin 2,882.00 10.00 0.35% -0.48%
Takeda 4,171.00 117.00 2.89% 23.26%
Astellas Pharma 1,889.50 -10.50 -0.55% -5.50%
Sumitomo Dainippon 861.00 2.00 0.23% -30.45%
Shionogi 6,207.00 14.00 0.23% -19.95%
Chugai Pharma 3,377.00 81.00 2.46% -15.15%
Eisai 7,869.00 -66.00 -0.83% 36.69%
Terumo 3,814.00 53.00 1.41% -10.24%
Daiichi Sankyo 4,061.00 21.00 0.52% 75.80%
Otsuka Holdings 4,087.00 -28.00 -0.68% 0.74%

Indexes Price Day Year
JP225 27504 101.69 0.37% 0.23%

Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Oceania), Asia and Latin America (South Korea, Taiwan, Hong Kong, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.